Fenbendazole and Ivermectin for Lung Cancer: 45 Case Reports Compilation (April 2026 Update)
Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...